Will AI create the world’s first trillionaire?<\/strong>\u00a0Our team just released a report on the one little-known company, called an “Indispensable Monopoly” providing the critical technology Nvidia and Intel both need.\u00a0Continue \u00bb<\/strong><\/a><\/p>\n Do you know how much it costs to bring a single drug to the market? The U.S. Department of Health and Human Services puts the average figure at nearly $900 million, although some equally credible estimates suggest the number can reach $2 billion, if not more. Worse, an estimate from the National Institutes of Health says that 9 out of 10 drugs that begin clinical trials ultimately don’t win approval. Never mind the years required to do all of these preclinical and clinical trials.<\/p>\n But what if there was a way to virtually do much of this research and development (R&D) work in a matter of hours, at a fraction of the usual cost? That’s what Recursion Pharmaceuticals<\/strong> (NASDAQ: RXRX) is offering customers.<\/p>\n It’s not a substitute for clinical trials, to be clear. However, leaning on more than 50 petabytes (52.4 million gigabytes) of chemical and biological data, Recursion’s AI-powered platform provides drug developers with a very good idea of how a drug might perform in the real world. This allows pharmaceutical companies to focus on their most promising prospects, and not waste resources on work that’s unlikely to pay off.<\/p>\n And this isn’t just theory. In addition to using its technology to pretest its own drugs, Recursion is partnering with more conventional pharma names like Sanofi<\/strong> and Roche Holding<\/strong> to develop the prospects of these third-party players.<\/p>\n It’s still pretty early on for its business. Most of its operating revenue so far is coming from its partner drugmakers paying to virtually test their R&D ideas. Last year was a pivotal one for the company, though, with developmental milestone payments starting to flow in earnest. Another big swell of revenue is expected next fiscal year after modest top-line growth this year. Recursion Pharmaceuticals is very much entering the AI-powered drug development market that Global Market Insights expects to grow at an average of 30% per year through 2035.<\/p>\n Story Continues <\/p>\n The other AI healthcare stock to consider buying sooner than later is more of a technology name than a healthcare one, but it’s a great opportunity all the same. That’s Tempus AI<\/strong> (NASDAQ: TEM).<\/p>\n Simply put, Tempus empowers caregivers. Its user interface looks and acts like an ordinary web portal, but it actually helps healthcare providers “make near real-time, data-driven decisions to deliver personalized patient care,” including the “discovery, development, and delivery of optimal therapeutics.” And no, there’s nothing else out there quite like it.<\/p>\n It’s not the premise that makes this stock such a compelling prospect, however. It’s that it’s already up, running, and off to the races. Tempus’ paying customers clearly like what they’re getting: The company’s fourth-quarter revenue of $367 million was up 83% year over year, pushing it ever closer to a breakeven that’s expected to materialize no later than the year after next.<\/p>\n This might convince you to take a swing on Tempus: Analysts’ current consensus target of $77.93 is 70% above the stock’s present price.<\/p>\n Before you buy stock in Recursion Pharmaceuticals, consider this:<\/p>\n The Motley Fool Stock Advisor analyst team just identified what they believe are the\u00a010 best stocks<\/a><\/strong> for investors to buy now\u2026 and Recursion Pharmaceuticals wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.<\/p>\n Consider when Netflix<\/strong> made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation,\u00a0you\u2019d have $503,861<\/strong>!* Or when Nvidia<\/strong> made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you\u2019d have $1,026,987<\/strong>!*<\/p>\n Now, it\u2019s worth noting\u00a0Stock Advisor\u2019s total average return is 884% \u2014 a market-crushing outperformance compared to 179% for the S&P 500.\u00a0Don’t miss the latest top 10 list, available with\u00a0Stock Advisor, and join an investing community built by individual investors for individual investors.<\/strong><\/p>\n See the 10 stocks \u00bb<\/strong><\/a><\/p>\n *Stock Advisor returns as of March 31, 2026. <\/p>\n James Brumley<\/a> has no position in any of the stocks mentioned. The Motley Fool recommends Roche Holding AG. The Motley Fool has a disclosure policy<\/a>.<\/p>\n![\"A](\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2026\/04\/7c7059ddf01a6d3e56ac8c8d95816104.jpeg\")
Image source: Getty Images. <\/p>\n